Persistence of Reduction in Blood Pressure and Mortality of Participants in the Hypertension Detection and Follow-up Program FREE

Neil Shulman, MD; Elbert Tuttle, Jr, MD; George Entwisle, MD; Aristide Apostolides, DVM, PhD; Albert Oberman, MD; Harold W. Schnaper, MD; Edward H. Kass, MD, PhD; James O. Taylor, MD; B. Frank Polk, MD; Jeremiah Stamler, MD; Rose Stamler, MA; Flora Gosch, MD; Nemat O. Borhani, MD; Beth Newman, PhD; Linda Harlan, PhD; Marshall Lee, MD; John W. Jones, MD; Sandra A. Daugherty, MD, PhD; H. A. Tyroler, MD; Curtis G. Hames, MD; Siegfried Heyden, MD; Lawrence M. Slotkoff, MD, PhD; Socrates Fotiu, MD; Herbert G. Langford, MD; John Abernathy, MD; Myra Tyler, MD; Morton H. Maxwell, MD; Andrew J. Lewin, MD; Roger Detels, MD; Reuben Berman, MD; Ronald J. Prineas, MB, BS, PhD; Richard S. Crow, MD; M. Donald Blaufox, MD, PhD; Sylvia Wassertheil-Smoller, PhD; C. Hilmon Castle, MD; Josephine Kasteller, PhD; C. Morton Hawkins, ScD; Charles E. Ford, PhD; Barry R. Davis, MD, PhD; Agostino Molteni, MD, PhD; Kenneth A. Schneider, MD; Edward J. Fitzsimmons, PhD; Ronald J. Prineas, MB, BS,; PhD; Gerald H. Payne, MD, MPH; Thomas P. Blaszkowski, PhD; William J. Zukel, MD; Alvin P. Shapiro, MD; Glenn E. Bartsch, PhD; Kenneth G. Berge, MD; Edward S. Cooper, MD; Edward D. Frohlich, MD; Richard H. Gadsden, PhD; David L. Sackett, MD; Joseph A. Wilber, MD; William J. Zukel, MD; W. McFate Smith, MD, MPH; Walter M. Kirkendall, MD; Curtis L. Meinert, PhD; Louis S. Monk, PhD; Richard D. Remington, PhD; Alvin P. Shapiro, MD; Herbert G. Langford, MD; Jeremiah Stamler, MD; Edward H. Kass, MD, PhD; Harold W. Schnaper, MD; Thomas P. Blaszkowski, PhD; Max Halperin, PhD; William J. Zukel, MD

[+] Author Affiliations

Members of the ad hoc committee that prepared this manuscript on behalf of the HDFP Cooperative Group were as follows: Sandra A. Daugherty, MD, PhD (University of Nevada, Reno); Charles E. Ford, PhD (The University of Texas School of Public Health, Houston); J. David Curb, MD (National Institute on Aging, Bethesda, Md); Herbert Langford, MD (University of Mississippi Medical Center, Jackson); James O. Taylor, MD (Harvard Medical School, Boston); Gerald H. Payne, MD (National Heart, Lung, and Blood Institute, Bethesda, Md); Nemat O. Borhani, MD (University of California at Davis); Sara Pressel, MS, and C. Morton Hawkins, ScD (The University of Texas School of Public Health, Houston).

Reprint requests to Coordinating Center for Clinical Trials, The University of Texas School of Public Health, 1200 Herman Pressler St, Suite 801, Houston, TX 77030 (Charles E. Ford, PhD).

JAMA. 1988;259(14):2113-2122. doi:10.1001/jama.1988.03720140033030

Text Size: A A A

Published online

Article

References

ABSTRACT

ABSTRACT | REFERENCES

The Hypertension Detection and Follow-up Program (HDFP) previously described a significant reduction in five-year, all-cause mortality in its intensively treated stepped care (SC) group relative to its referred care (RC) control group. At the time this finding was described, a proportion of the SC cohort had been treated for periods as long as 6.7 years, but comparable RC and SC mortality data beyond five years were not available. These data, which are described herein, indicate that the 6.7-year life-table mortality rates were 95.1/1000 participants for SC vs 116.3/1000 participants for RC, a larger mortality difference than was observed at five years. This favorable finding for SC extended to all major subgroups, including white women and those aged 30 to 49 years at trial entry. Six months after the close of the treatment trial, a two-year posttrial surveillance study, which extended mortality follow-up to 8.3 years, was conducted. The posttrial use of antihypertensive medication declined in SC and increased in RC participants so that by the end of the posttrial period, there was little difference in the percentages of SC and RC participants taking medication. Control of blood pressure, indicated by mean diastolic blood pressure and by percent of participants with a pressure of 90 mm Hg or less, was slightly better for SC than for RC participants (SC group, 86.5 mm Hg and 68% controlled; RC group, 87.8 mm Hg and 62% controlled). The absolute mortality advantage found at 6.7 years persisted and increased throughout the posttrial period of follow-up despite discontinuation of the formal SC therapy program. It is postulated that regression of hypertensive end-organ changes brought about by the more effective SC treatment caused this favorable outcome.

(JAMA 1988;259:2113-2122)

REFERENCES

ABSTRACT | REFERENCES

Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;;242:2562-2571.

Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: II. Mortality by race-sex and age. JAMA 1979;;242:2572-2577.

Hypertension Detection and Follow-up Program Cooperative Group: Implications of the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis 1986;;29( (suppl 1) ):3-10.

Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982;;247:633-638.

Daugherty SA, Berman R, Entwisle G, et al: Cerebrovascular events in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis 1986;;29( (suppl 1) ):63-72.

Hypertension Detection and Follow-up Program Cooperative Group: Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. Hypertension 1984;;6( (suppl 1) ):198-206.

Borhani NO, Blaufox MD, Oberman A, et al: Incidence of coronary heart disease and left ventricular hypertrophy in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis 1986;;29( (suppl 1) ):55-62.

Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985;;7:105-112.

Hardy RJ, Hawkins CM: The impact of selected indices of antihypertensive treatment on all-cause mortality. Am J Epidemiol 1983;;117:566-574.

Hypertension Detection and Follow-up Program Cooperative Group: The Hypertension Detection and Follow-up Program. Prev Med 1976;;5:207-215.

Davis BR, Ford CE, Remington RD, et al: The Hypertension Detection and Follow-up Program: Design, methods, and baseline characteristics and blood pressure response of the study population. Prog Cardiovasc Dis 1986;;29( (suppl 1) ):11-28.

Hypertension Detection and Follow-up Program Cooperative Group: Blood pressure studies in 14 communities: A two-stage screen for hypertension. JAMA 1977;;237:2385-2391.

Curb JD, Ford CE, Pressel S, et al: Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol 1985;;121:754-766.

Lee ET: Statistical Methods for Survival Analysis . Belmont, Calif, Lifetime Learning Publications, 1980;, pp 88-101.

Cutler S, Ederer F: Maximum utilization of the life-table method in analyzing survival. J Chronic Dis 1958;;8:699-712.

Curb JD, Babcock C, Pressel S, et al: Nosological coding of cause of death. Am J Epidemiol 1983;;118:122-128.

Silvertsson R, Hansson L: Effect of blood pressure reduction on the structural abnormality in skin and muscle in human essential hypertension. Clin Sci 1976;;51:775-795.

Langford HG, Blaufox MD, Oberman A, et al: Dietary therapy slows the return of hypertension after stopping medication. JAMA 1985;;253:657-664.

Stamler R, Stamler J, Grimm R, et al: Nutritional therapy for high blood pressure: Final report of a four-year randomized controlled trial—The Hypertension Control Program. JAMA 1987;;257: 1484-1491.

Maland LJ, Lutz LJ, Castle CH: Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertension 1983;;5:539-544.

Amery A, Brixko P, Clement D, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;;1:1349-1354.

Curb JD, Hardy RJ, Labarthe DR, et al: Reserpine and breast cancer in the Hypertension Detection and Follow-up Program. Hypertension 1982;;4:307-311.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal